皮肤微生物组在痤疮与特应性皮炎治疗中的新兴效用
本文综述了皮肤微生物组在特应性皮炎和寻常痤疮发病、预后及治疗靶点中的作用。现有治疗以控制特定病原体相关炎症为主,但共生微生物群在疾病缓解中起重要作用。靶向生物疗法调节微生物群落可能革新炎症性皮肤病的治疗方式。
要点
- 皮肤共生微生物群在特应性皮炎和痤疮的疾病缓解中起重要作用。
- 现有抗菌治疗虽有效,但存在不良反应和抗菌素耐药风险。
- 靶向调节微生物组的生物疗法有望革新炎症性皮肤病的治疗。
核心结论
- 皮肤微生物组在特应性皮炎和寻常痤疮的发病、预后及治疗中具有潜在干预价值。
- 靶向调节微生物群落的生物疗法可能革新炎症性皮肤病的治疗方式。
研究设计与样本
- 本文为综述,检索并汇总了关于皮肤微生物组在特应性皮炎和寻常痤疮中作用的证据。
主要发现
- 研究强调皮肤微生物群在特应性皮炎和寻常痤疮的发病机制、预后判断和治疗干预靶点中的重要性。
- 自然存在于皮肤的共生微生物群已被证明在疾病发作缓解中起重要作用。
临床怎么用
- 当前管理旨在使用局部和全身抗菌药物控制与特定病原体相关的炎症反应。
- 需关注现有主流治疗的不良反应及抗菌素耐药问题。
- 可考虑靶向微生物组的生物疗法作为炎症性皮肤病的新治疗方向。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The cutaneous microbiome has potential for therapeutic intervention in inflammatory-driven skin disease. Research into atopic dermatitis and acne vulgaris has highlighted the importance of the skin microbiota in disease pathogenesis, prognostication, and targets for therapeutic intervention. Current management of these conditions aims to control the inflammatory response thought to be associated with specific pathogens using both topical and systemic antimicrobials. However, commensal microbiota found naturally on the skin have been shown to play an important role in the resolution of disease flares. Although often efficacious, the mainstay treatments are not without adverse effects and raise concerns regarding the development of antimicrobial resistance. Augmentation of microbial communities with targeted biotherapy could revolutionize the way inflammatory conditions of the skin are treated. Herein, we review evidence for the role of the cutaneous microbiome in atopic dermatitis and acne vulgaris and suggest that these conditions highlight the potential for microbiome-directed therapeutics.
引用
- Woo TE, Sibley CD. The emerging utility of the cutaneous microbiome in the treatment of acne and atopic dermatitis. J Am Acad Dermatol. 2019. PMID: 31499149. doi:10.1016/j.jaad.2019.08.078
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。